BIOMATZ is an innovative biotechnology company that provides tailor-made microbiome solutions based on the nation’s largest strain data bank (approximately 10,000 strains) and its proprietary AI-driven microbial consortium design platform, BASyMCo (Bespoke Assembly of Synthetic Microbial Consortia).
The BASyMCo platform consists of three core components:
1)Bank – A strain databank comprising live microbial resources and growth curve data
2)Lab – Multi-omics analyses and microbial interaction network mapping
3)Solver – An AI-powered algorithm for designing optimal synthetic microbial consortia
Through this integrated system, BASyMCo can be applied across multiple industries, including pharmaceuticals (LBP, targeting liver diseases and immuno-oncology), functional foods (respiratory health and obesity), and smart farming (Biostimulants).
Unlike conventional single-strain approaches, BASyMCo enables the design of microbial consortia with superior colonization, stability, and efficacy while significantly reducing development time and cost, thereby proving its differentiated growth potential in the global market.
We are currently collaborating with a global CDMO partner on the development of a live biotherapeutic for atopic dermatitis, aiming to complete the production study of a topical prototype formulation by Q3 2025. Following this milestone, we plan to initiate investigator-initiated clinical trials and advance the development of veterinary pharmaceuticals.